The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Umbralisib with ibrutinib in patients with R/R CLL or MCL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, updates us on long-term results of a Phase Ib study investigating ibrutinib with umbralisib, a PI3Kdelta inhibitor, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
